Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c‐Met Expression
Phytotherapy Research · 2026
DOI: 10.1002/ptr.70176 ↗At a glance
Journal article in Phytotherapy Research, 2026. Written by Yiqun Song and 7 co-authors. Institution: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Major MEDLINE topics: Lignans, Pancreatic Neoplasms, Biphenyl Compounds, Neoplastic Stem Cells. 59 references. Funded by: National Natural Science Foundation of China, Innovative Team Foundation of Shaanxi Health Commission, Key Research and Development Program of Shaanxi.
Abstract (original language)
Due to its high recurrence and metastasis rates, the prognosis of pancreatic cancer (PC) patients is extremely poor. Cancer stem cells (CSCs) are the major source of occurrence and progression of PC, suggesting that targeting pancreatic CSC stemness may provide therapeutic benefits. This study aims to clarify the mechanisms by which Honokiol (HNK) inhibits the stemness of pancreatic cancer. The expression of c‐Met and downstream molecules was investigated based on public databases and also confirmed by the immunohistochemistry (IHC) staining of human tissues. Colony formation assay and sphere formation assay were conducted to verify the effect of HNK on the proliferation and stemness of PC cells. A subcutaneous transplanted tumor model of BALB/c nude mice was established to explore the effect of HNK on modulating the tumor growth of PC in vivo. c‐Met expression was significantly elevated in PC tissues versus normal pancreas tissues, and the high level of c‐Met was positively correlated with poor prognosis of PC patients. Overexpression of c‐Met significantly enhanced the proliferation and stemness of cancer cells, whereas HNK treatment reversed these effects. Critically, HNK suppressed tumor growth in vivo by downregulating c‐Met. Our study reveals that HNK reduced the proliferation and stemness of PC cells via suppressing the c‐Met overexpression. These findings provide a potential therapeutic method for PC, offering new hope for improving patients' outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Pancreatic Disease Center of Xi'an Jiaotong University, Xi'an, China.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID profiles: Zheng Wang, Tao Qin
Funding
- National Natural Science Foundation of China
- Innovative Team Foundation of Shaanxi Health Commission
- Key Research and Development Program of Shaanxi
- Key Research and Development Projects of Shaanxi Province
Cite
APA
Song, Y., Zeng, J., Wu, J., Chen, X., Feng, Z., Qian, W., Wang, Z., & Qin, T. (2026). Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c‐Met Expression. Phytotherapy Research. https://doi.org/10.1002/ptr.70176
Vancouver
Song Y, Zeng J, Wu J, Chen X, Feng Z, Qian W, et al. Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c‐Met Expression. Phytotherapy Research. 2026. doi:10.1002/ptr.70176
BibTeX
@article{Song2026,
author = {Song, Yiqun and Zeng, Jiahui and Wu, Jiaoxing and Chen, Xinlong and Feng, Zhengyuan and Qian, Weikun and Wang, Zheng and Qin, Tao},
title = {Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c‐Met Expression},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70176}
}
EUVIMED